تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
5.38 US$
+0.11 US$ · +2.09%
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
الإغلاق السابق
5.38 US$
+0.11 US$ · +2.09%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
نطاق اليوم
السعر الحالي 5.38 US$
نطاق 52 أسبوعًا
السعر الحالي 5.38 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
33
مرتفع السعر
المشاعر
74
صعودي
المخاطر
80
مخاطر مرتفعة
الزخم
39
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
نطاق اليوم
السعر الحالي 5.38 US$
نطاق 52 أسبوعًا
السعر الحالي 5.38 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI5.82 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM2.31 مليون0.00%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF2.16 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
Vanguard Russell 2000 ETFVTWO1.03 مليون0.01%18 مليار USD0.06%112.66 US$+0.50%
Dimensional - US Small Cap ETFDFAS525.27 ألف0.00%33.87 مليار USD0.31%78.35 US$+0.32%
Fidelity Enhanced Small Cap ETFFESM482.7 ألف0.01%6.41 مليار USD0.28%45.46 US$+0.46%
iShares Micro-Cap ETFIWC284.21 ألف0.02%1.32 مليار USD0.60%183 US$+0.11%
U.S. Micro Cap Portfolio ETFDFMC209.32 ألف0.00%7.56 مليار USD0.43%57.813 US$+0.20%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
